Search

Displaying results 3291 - 3300 of 8575 in total
  1. Drug

    Arundic acid

    go.drugbank.com/drugs/DB05343
    Investigational

    Arundic acid has been investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).

  2. Drug

    Salsalate

    go.drugbank.com/drugs/DB01399
    ApprovedInvestigational

    The usefulness of salicylic acid, the active in vivo product of salsalate, in the treatment of arthritic disorders has been established. … Salsalate's mode of action as an anti-inflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins.

    Products: Disalcid Tab 500mg, Disalcid - Tab 500mg
  3. Drug

    Bremelanotide

    go.drugbank.com/drugs/DB11653
    Approved

    [L9635] Bremelanotide was first described in the literature in 2003 when it was known by the investigational code PT-141. … [A179689] Bremelanotide was granted FDA approval on 21 June 2019.[L9635]

  4. Drug

    Natamycin

    go.drugbank.com/drugs/DB00826
    ApprovedInvestigational

    Amphoteric macrolide antifungal antibiotic from Streptomyces natalensis or S. chattanoogensis. It is used for a variety of fungal infections, mainly topically. [PubChem]

  5. Drug

    Insulin beef

    go.drugbank.com/drugs/DB09456
    Approved

    Insulin beef has been discontinued in the US and Canada since 2017.[L10827]

  6. Drug

    Oxatomide

    go.drugbank.com/drugs/DB12877
    Approved

    Oxatomide has been used in trials studying the treatment of Muscular Dystrophy, Duchenne.

  7. Drug

    Parthenolide

    go.drugbank.com/drugs/DB13063
    ApprovedInvestigational

    Parthenolide has been used in trials studying the diagnostic of Allergic Contact Dermatitis.

  8. Drug

    Butaperazine

    go.drugbank.com/drugs/DB13213
    Approved

    Butaperazine was approved in 1967 [L5143], and possibly discontinued in the 1980s [T397].

  9. Drug

    Sebelipase alfa

    go.drugbank.com/drugs/DB11563
    ApprovedInvestigational

    It was first approved by both the FDA and EMA in 2015 and is marketed under the brand name Kanuma (Alexion Pharmaceuticals).[L39337,L39342]

  10. Drug

    Veglin

    go.drugbank.com/drugs/DB05890
    Experimental

    VEGF-AS (Veglin) is an anti-angiogenesis non-chemotherapy drug (angiogenesis inhibitor) that was developed by VasGene Therapeutics, Inc. for the treatment of a variety of malignancies including mesothelioma

    Synonyms: VEGF-AS